A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In this study subjects will be administered a single oral dose of Aminolevulinic Acid (ALA) prior to surgical resection of their brain tumor. The ALA ultimately causes brain tumor tissue to fluoresce or light up under ultraviolet light. During surgery an ultraviolet light in the microscope chain will be turned on. The tumor tissue will fluoresce bright pink allowing the surgeon to more easily differentiate tumor tissue from normal brain tissue. The aim of the study is to determine whether ALA and fluorescent visualization of tumor tissue improves the surgeon's ability to completely resect or remove the brain tumor.
| Condition | Intervention | Phase |
|---|---|---|
|
Malignant Glioma Glioma Glioblastoma Glioblastoma Multiforme Astrocytoma |
Drug: Aminolevulinic Acid |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain |
- Time to disease progression after initial surgery. [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]Determine time-to-progression compared to that in comparable cases performed without the aid of ALA.
- Complete Resection [ Time Frame: Day 2 ] [ Designated as safety issue: No ]Determine the percentage of patients with complete resections of contrast-enhancing tumor, compared to historical controls
- Determine the number of subjects with adverse events due to ALA in this dosage and indication. [ Time Frame: Through 45 days ] [ Designated as safety issue: Yes ]Subjects will be followed closely for adverse events including biochemical abnormalities through laboratory monitoring and for clinically evident adverse events including possible skin reactions that may occur.
- Overall Survival [ Time Frame: Up to three years ] [ Designated as safety issue: No ]Determine the overall survival compared to historical controls.
| Estimated Enrollment: | 60 |
| Study Start Date: | May 2011 |
| Estimated Primary Completion Date: | May 2014 (Final data collection date for primary outcome measure) |
-
Drug: Aminolevulinic Acid
- ALA
- 5-Aminolevulinic Acid
- Levulan
This is a Phase 2 study and all subjects will receive open label Aminolevulinic Acid in a dose of 20mg/kg given orally 3 hours prior to surgery. Brain tumors will be resected with the aid of ultraviolet light to visualize the tumor. After surgery an MRI will be done to determine whether the tumor has been completely or partially resected. All subjects will be followed for safety. All subjects will be followed closely by clinical examination and by MRI to monitor for disease recurrence.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinically documented primary brain tumor for which surgical resection is indicated.
- Age 18 years and older.
- ECOG Performance status less than or equal to 2.
- Laboratory values as follows:
Leukocytes greater than or equal to 3,000. ANC greater than or equal to 1,500. Platelets greater than or equal to 100,000. Total Bilirubin WNL. AST/ALT less than or equal to 2.5 times ULN. Creatinine WNL. or Creatinine Clearance greater than or equal to 60ml/min/1.73m2 if SCr above institutional normal.
-Ability to provide informed consent or consent from a Legally Authorized Representative.
Exclusion Criteria:
- Receipt of an investigational agent within 30 days.
- Allergy to ALA or similar compounds.
- Personal or family history of porphyria.
- Uncontrolled intercurrent illness.
- Inability to comply with the protocol.
- Pregnancy, breastfeeding.
Contacts and Locations| Contact: Diane Miller, RN, MSN | 253-403-5265 | diane.miller@multicare.org |
| Contact: Christine Goetz, BS | 253-403-7193 | christine.goetz@multicare.org |
| United States, Washington | |
| MultiCare Health System Research Institute | Recruiting |
| Tacoma, Washington, United States, 98405 | |
| Contact: Richard Shine, PharmD, BCPS 253-403-7250 richard.shine@multicare.org | |
| Principal Investigator: William Morris, MD | |
| Sub-Investigator: Peter Brown, MD | |
| Sub-Investigator: Anthony Harris, MD, PhD | |
| Principal Investigator: | William Morris, MD | MultiCare Health System |
| Study Director: | Richard Shine, PharmD, BCPS | MultiCare Health System Research Institute |
More Information
Publications:
| Responsible Party: | William Morris, MD, Principal Investigator, MultiCare Health System Research Institute |
| ClinicalTrials.gov Identifier: | NCT01351519 History of Changes |
| Other Study ID Numbers: | ALA 11.07 |
| Study First Received: | May 7, 2011 |
| Last Updated: | May 9, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by MultiCare Health System Research Institute:
|
Glioma Glioblastoma Glioblastoma Multiforme Astrocytoma Brain Tumor |
Additional relevant MeSH terms:
|
Astrocytoma Brain Neoplasms Glioblastoma Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Central Nervous System Neoplasms |
Nervous System Neoplasms Neoplasms by Site Brain Diseases Central Nervous System Diseases Nervous System Diseases Aminolevulinic Acid Photosensitizing Agents Radiation-Sensitizing Agents Physiological Effects of Drugs Pharmacologic Actions Dermatologic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 21, 2013